CNTX – context therapeutics inc. (US:NASDAQ)
Stock Stats
News
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 [Yahoo! Finance]
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Context Therapeutics names Andy Pasternak as chair [Seeking Alpha]
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Form SCHEDULE 13G/A Context Therapeutics Filed by: Blue Owl Capital Holdings LP
Form SCHEDULE 13G/A Context Therapeutics Filed by: GREAT POINT PARTNERS LLC
Form 4 Context Therapeutics For: Feb 13 Filed by: Minai-Azary Jennifer Lynn
Form 4 Context Therapeutics For: Feb 13 Filed by: Levit Alex C.
Form 4 Context Therapeutics For: Feb 13 Filed by: Dansky Ullmann Claudio
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.